| 摘要 |
The invention features human CR3 alpha recombinant or synthetic peptide capable of inhibiting a CR3-mediated immune response, a purified DNA encoding a human CR3 alpha peptide, and a method of controlling any phagocyte-mediated tissue damage such as that associated with reduced perfusion of heart tissue during acute cardiac insufficiency. As used herein, a human CR3 alpha recombinant peptide is a chain of amino acids derived from recombinant CR3 alpha -encoding cDNA, or the corresponding synthetic DNA.
|
